Press

Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami

Sep 8 • 5 min read

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW0 | OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce that it will be the Headline Sponsor for Wonderland, the world-leading academic and business gathering in the psychedelic medicine industry, which will be held in Miami from November 3-5th, 2022 at the Mana Wynwood Convention Centre. Christopher J….

Optimi Health Completes Largest Legal Natural Psilocybin Harvest in Canadian History

Sep 8 • 4 min read

Optimi Health Corp. (CSE: OPTI | OTCQX: OPTHF | FRA: 8BN), is pleased to announce that it has completed what it believes to be the largest legal natural psilocybin harvest in Canadian history. The Company is licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, most notably MDMA, as…

MindMed Announces Positive Results from Collaborators’ Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal

Sep 8 • 4 min read

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD | NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that the manuscript “Lysergic Acid Diethylamide-Assisted Therapy In Patients With Anxiety With And Without A Life-Threatening Illness A Randomized, Double-Blind, Placebo-Controlled Phase II Study,” has been published in the peer-reviewed scientific…

Psyence Group Announces Amendment and Closing of Previously Announced Private Placement

Sep 8 • 4 min read

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce, further to the Company’s press release dated December 2, 2021, the amendment and closing of its first tranche of the previously announced non-brokered private placement offering raising gross proceeds…

Nirvana Life Sciences Inc. Announces a Method for Producing MDMA that Reduces Manufacturing Time by Two Thirds

Sep 7 • 4 min read

Nirvana Life Sciences Inc. (CSE: NIRV), a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing pharmaceutical medicines and formulations to be used in trauma work, is pleased to report the development of a more efficient method for producing MDMA. Nirvana Life Sciences Inc. is…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441